Moors & Cabot, Inc. Lineage Cell Therapeutics, Inc. Transaction History

Moors & Cabot, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$1.84 - $2.68 $11,040 - $16,080	-6,000 Reduced 32.61%	12,400 $30,000
Q3 2021 Dec 08, 2021	BUY	$2.26 - $2.86 $41,583 - $52,624	18,400 New	18,400 $47,000
Q3 2021 Nov 05, 2021	SELL	$2.26 - $2.86 $52,793 - $66,809	-23,360 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$2.17 - $3.0 $8,007 - $11,070	3,690 Added 18.76%	23,360 $67,000
Q1 2021 May 12, 2021	BUY	$1.77 - $3.1 $6,938 - $12,152	3,920 Added 24.89%	19,670 $46,000
Q4 2020 Feb 11, 2021	BUY	$0.95 - $1.83 $950 - $1,830	1,000 Added 6.78%	15,750 $27,000
Q3 2020 Nov 09, 2020	SELL	$0.75 - $1.09 $1,050 - $1,526	-1,400 Reduced 8.67%	14,750 $14,000
Q2 2020 Aug 13, 2020	SELL	$0.71 - $1.18 $2,840 - $4,720	-4,000 Reduced 19.85%	16,150 $14,000
Q4 2019 Jan 28, 2020	SELL	$0.54 - $1.01 $8,100 - $15,150	-15,000 Reduced 42.67%	20,150 $18,000
Q3 2019 Oct 22, 2019	BUY	$0.85 - $1.24 $29,877 - $43,586	35,150 New	35,150 $34,000

134

106M

22.1K

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $115M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

Get notified when there are updates to the investment portfolio of Moors & Cabot, Inc., based on Form 13F filings with the SEC.

Stay updated on Moors & Cabot, Inc. with notifications on news.